Ergomed (ERGO) Receives Buy Rating from Numis Securities

Ergomed (LON:ERGO)‘s stock had its “buy” rating reissued by equities researchers at Numis Securities in a research report issued on Thursday. They currently have a GBX 300 ($4.21) price target on the stock. Numis Securities’ target price suggests a potential upside of 50.75% from the company’s current price.

Separately, N+1 Singer reaffirmed a “corporate” rating on shares of Ergomed in a report on Friday, December 15th.

Shares of Ergomed (LON:ERGO) remained flat at $GBX 199 ($2.79) on Thursday. 8,417 shares of the company were exchanged, compared to its average volume of 51,971. Ergomed has a 12 month low of GBX 165 ($2.32) and a 12 month high of GBX 225 ($3.16). The firm has a market capitalization of $124.90 and a PE ratio of 19,900.00.

In related news, insider Peter George acquired 500,000 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was acquired at an average cost of GBX 190 ($2.67) per share, with a total value of £950,000 ($1,334,082.29).

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at

About Ergomed

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services.

Receive News & Ratings for Ergomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed and related companies with's FREE daily email newsletter.

Leave a Reply